

Peter A Mccullough

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2872733/peter-a-mccullough-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

378
papers

20,958
citations

64
h-index

138
g-index

430
ext. papers

24,426
ext. citations

4.9
avg, IF

6.94
L-index

#	Paper	IF	Citations
378	Clinical Utility of a Biomarker to Detect Contrast-Induced Acute Kidney Injury during Percutaneous Cardiovascular Procedures.. <i>CardioRenal Medicine</i> , 2022 , 1-9	2.8	0
377	Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients.. <i>Future Microbiology</i> , 2022 ,	2.9	3
376	Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.. <i>Food and Chemical Toxicology</i> , 2022 , 113008	4.7	3
375	Implications of Chronic Kidney Disease on the Epidemiology of Cardiovascular Disease 2021 , 1-5		
374	Novel Biomarkers of Chronic Cardiorenal Disease 2021 , 227-233		
373	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 2039-2048	4.3	6
372	The Reply. <i>American Journal of Medicine</i> , 2021 , 134, e222-e223	2.4	0
371	Screening for SARS-CoV-2 via PCR and serological testing in asymptomatic healthcare workers. <i>Baylor University Medical Center Proceedings</i> , 2021 , 34, 437-441	0.6	
370	Nomenclature in nephrology: preserving RenalRand NephroRin the glossary of kidney health and disease. <i>Journal of Nephrology</i> , 2021 , 34, 639-648	4.8	2
369	The Reply. <i>American Journal of Medicine</i> , 2021 , 134, e298	2.4	
368	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021 , 384, 1601-1612	59.2	23
367	Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. <i>New England Journal of Medicine</i> , 2021 , 384, 1589-1600	59.2	30
366	Anemia of cardiorenal syndrome. <i>Kidney International Supplements</i> , 2021 , 11, 35-45	6.3	8
365	Comparison of Survival in Patients With Clinically Significant Tricuspid Regurgitation With and Without Heart Failure (From the Optum Integrated File). <i>American Journal of Cardiology</i> , 2021 , 144, 125-130	3.3	1
364	Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1435-1444	6.9	0
363	Serum creatinine and cystatin C-based estimates of glomerular filtration rate are misleading in acute heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 3070-3081	3.7	3
362	Six-Month Outcomes for COVID-19 Negative Patients with Acute Myocardial Infarction Before Versus During the COVID-19 Pandemic. <i>American Journal of Cardiology</i> , 2021 , 147, 16-22	3	4

361	The Reply. <i>American Journal of Medicine</i> , 2021 , 134, e346-e347	2.4	
360	The Reply. <i>American Journal of Medicine</i> , 2021 , 134, e343-e344	2.4	
359	Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality. <i>CardioRenal Medicine</i> , 2021 , 11, 123-132	2.8	2
358	Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36, 137-150	4.3	14
357	Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. <i>American Journal of Medicine</i> , 2021 , 134, 16-22	2.4	55
356	Healthcare utilization in clinically significant tricuspid regurgitation patients with and without heart failure. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 29-37	2.1	0
355	Role of Ischemic Heart Disease in Major Adverse Renal and Cardiac Events Among Individuals With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). <i>American Journal of Cardiology</i> , 2021 , 142, 91-96	3	1
354	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021 , 235, 1-11	4.9	4
353	Role of endothelial cell receptors in the context of SARS-CoV-2 infection (COVID-19). <i>Baylor University Medical Center Proceedings</i> , 2021 , 34, 262-268	0.6	2
352	Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure: invasive hemodynamic parameters and clinical outcomes. <i>Reviews in Cardiovascular Medicine</i> , 2021 , 22, 199-206	3.9	1
351	Screening, detection, and management of heart failure in the SARS-CoV2 (COVID-19) pandemic. <i>Heart Failure Reviews</i> , 2021 , 26, 973-979	5	2
350	Regarding: "Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019". <i>Annals of Medicine</i> , 2021 , 53, 286	1.5	
349	Major Adverse Renal and Cardiovascular Events following Intra-Arterial Contrast Media Administration in Hospitalized Patients with Comorbid Conditions. <i>CardioRenal Medicine</i> , 2021 , 11, 193-199	2.8	0
348	The Reply. <i>American Journal of Medicine</i> , 2021 , 134, e440-e441	2.4	
347	The Reply. <i>American Journal of Medicine</i> , 2021 , 134, e464	2.4	
346	Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents. <i>Medical Hypotheses</i> , 2021 , 153, 110622	3.8	6
345	Synthetic mRNAs; Their Analogue Caps and Contribution to Disease. <i>Diseases (Basel, Switzerland)</i> , 2021 , 9,	4.4	1
344	Impact of renin-angiotensin-aldosterone system inhibitor continuation on outcomes for patients with severe coronavirus disease 2019 manifestations. <i>Journal of Hypertension</i> , 2021 , 39, 1725-1726	1.9	2

343	Measuring the Variation in the Prevention and Treatment of CI-AKI Among Interventional Cardiologists. <i>Current Problems in Cardiology</i> , 2021 , 46, 100851	17.1	2
342	Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021.. <i>Medical Science Monitor</i> , 2021 , 27, e935379	3.2	3
341	Fulminant Acute Kidney Injury in a Young Patient with Novel Coronavirus 2019. <i>CardioRenal Medicine</i> , 2020 , 10, 217-222	2.8	11
340	Impact of mitral regurgitation on cardiovascular hospitalization and death in newly diagnosed heart failure patients. <i>ESC Heart Failure</i> , 2020 , 7, 1502-1509	3.7	2
339	Antihypertensive drugs and risk of COVID-19?. <i>Lancet Respiratory Medicine</i> , 2020 , 8, e29	35.1	13
338	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of Nephrology</i> , 2020 , 51, 276-288	4.6	5
337	Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020 , 131, 1-6	3	46
336	Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure. <i>CardioRenal Medicine</i> , 2020 , 10, 69-84	2.8	14
335	The economic impact of clinically significant tricuspid regurgitation in a large, administrative claims database. <i>Journal of Medical Economics</i> , 2020 , 23, 521-528	2.4	2
334	Delays in Presentation in Patients With Acute Myocardial Infarction During the COVID-19 Pandemic. <i>Cardiology Research</i> , 2020 , 11, 386-391	1.8	23
333	A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine 2020 , 449-461		
332	Contrast induced acute kidney injury in interventional cardiology: an update and key guidance for clinicians. <i>Reviews in Cardiovascular Medicine</i> , 2020 , 21, 9-23	3.9	9
331	Predictors of 30-day re-admissions in patients with infective endocarditis: a national population based cohort study. <i>Reviews in Cardiovascular Medicine</i> , 2020 , 21, 123-127	3.9	2
330	Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. <i>Reviews in Cardiovascular Medicine</i> , 2020 , 21, 315-319	3.9	68
329	Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19. <i>Reviews in Cardiovascular Medicine</i> , 2020 , 21, 339-344	3.9	20
328	Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. <i>Reviews in Cardiovascular Medicine</i> , 2020 , 21, 611-614	3.9	20
327	Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). <i>Reviews in Cardiovascular Medicine</i> , 2020 , 21, 517-530	3.9	29
326	Early multidrug regimens in new potentially fatal medical problems. <i>Reviews in Cardiovascular Medicine</i> , 2020 , 21, 507-508	3.9	1

325	Mediators of the Effects of Canagliflozin on Heart Failure: Central Role of the Cardiorenal Axis. <i>JACC: Heart Failure</i> , 2020 , 8, 426	7.9	
324	The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. <i>CardioRenal Medicine</i> , 2020 , 10, 1-10	2.8	45
323	Impact of Durable Ventricular Assist Device Support on Outcomes of Patients with Congenital Heart Disease Waiting for Heart Transplant. <i>ASAIO Journal</i> , 2020 , 66, 513-519	3.6	7
322	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study 2020 , 2, e0220		1
321	Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome. <i>Journal of the American Heart Association</i> , 2020 , 9, e017364	6	18
320	Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19). <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	12
319	Mortality Risk Assessment Using CHA(2)DS(2)-VASc Scores in Patients Hospitalized With Coronavirus Disease 2019 Infection. <i>American Journal of Cardiology</i> , 2020 , 137, 111-117	3	12
318	Disconnect between community testing and hospitalization for SARS-CoV-2 (COVID-19) infection. <i>Baylor University Medical Center Proceedings</i> , 2020 , 33, 481	0.6	3
317	Meta-analysis of outcomes of patients with COVID-19 infection with versus without gastrointestinal symptoms. <i>Baylor University Medical Center Proceedings</i> , 2020 , 33, 366-369	0.6	11
316	Usefulness of coronary angiography in patients with left atrial myxoma. <i>Baylor University Medical Center Proceedings</i> , 2020 , 33, 529-531	0.6	
315	COVID-19-Associated Systemic Thromboembolism: A Case Report and Review of the Literature. <i>CardioRenal Medicine</i> , 2020 , 10, 462-469	2.8	5
314	Current Overview on Hypercoagulability in COVID-19. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 393-403	4	96
313	Considerations for Management of Acute Coronary Syndromes During the SARS-CoV-2 (COVID-19) Pandemic. <i>American Journal of Cardiology</i> , 2020 , 131, 115-119	3	5
312	Ventricular Septal Myectomy for the Treatment of Left Ventricular Outflow Tract Obstruction Due to Fabry Disease. <i>American Journal of Cardiology</i> , 2020 , 132, 160-164	3	1
311	Limitations of transoesophageal echocardiogram in acute ischaemic stroke. <i>Open Heart</i> , 2020 , 7, e001175		1
310	Acute coronary syndromes in the peri-operative period after kidney transplantation in United States. <i>Clinical Transplantation</i> , 2020 , 34, e14083	3.8	3
309	Ventricular Fibrillation Storm in Coronavirus 2019. <i>American Journal of Cardiology</i> , 2020 , 135, 177-180	3	11
308	Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 919-930	2.5	14

307	SARS-CoV-2 (COVID-19) and intravascular volume management strategies in the critically ill. <i>Baylor University Medical Center Proceedings</i> , 2020 , 1-6	0.6	24
306	Comparison of reflex, resistance training, and core activities using change in blood pressure over time after spontaneous coronary artery dissection. <i>Baylor University Medical Center Proceedings</i> , 2019 , 32, 113-115	0.6	2
305	The healthcare burden of disease progression in medicare patients with functional mitral regurgitation. <i>Journal of Medical Economics</i> , 2019 , 22, 909-916	2.4	2
304	Development and Initial Validation of the PROMIS [®] -Plus-HF Profile Measure. <i>Circulation: Heart Failure</i> , 2019 , 12, e005751	7.6	9
303	Cardiovascular disease care fragmentation in kidney transplantation: a call for action. <i>Kidney International</i> , 2019 , 96, 568-571	9.9	4
302	Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 798-809	6.9	64
301	Cardiorenal Syndrome Type 1 2019 , 677-689.e2		
300	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019 , 96, 1030-1036	9.9	15
299	Community-Acquired Acute Kidney Injury as a Risk Factor of de novo Heart Failure Hospitalization. <i>CardioRenal Medicine</i> , 2019 , 9, 252-260	2.8	4
298	Cardiometabolic-Renal Disease in South Asians: Consensus Recommendations from the Cardio Renal Society of America. <i>CardioRenal Medicine</i> , 2019 , 9, 240-251	2.8	1
297	Arterial Stiffness in the Heart Disease of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 918-928	12.7	53
296	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019 , 95, 1304-1317	9.9	96
295	Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 760-773	4.3	47
294	Event dependence in the analysis of cardiovascular readmissions postpercutaneous coronary intervention. <i>Journal of Investigative Medicine</i> , 2019 , 67, 943-949	2.9	1
293	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019 , 139, e840-e878	16.7	301
292	Frequency of abnormal fractional flow reserve measurements among major coronary arteries. <i>Cardiovascular Revascularization Medicine</i> , 2019 , 20, 143-146	1.6	0
291	First and recurrent events after percutaneous coronary intervention: implications for survival analyses. <i>Scandinavian Cardiovascular Journal</i> , 2019 , 53, 299-304	2	0
290	Class effects of SGLT2 inhibitors on cardiorenal outcomes. <i>Cardiovascular Diabetology</i> , 2019 , 18, 99	8.7	71

289	Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2019 , 9, 316-325	2.8	3
288	Clinical Context of Dyskalemias Across the Heart Failure Spectrum and Their Associated Adverse Outcomes. <i>JACC: Heart Failure</i> , 2019 , 7, 533	7.9	0
287	Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness. <i>CardioRenal Medicine</i> , 2019 , 9, 358-369	2.8	9
286	The Economic Impact of Mitral Regurgitation on Patients With Medically Managed Heart Failure. <i>American Journal of Cardiology</i> , 2019 , 124, 1226-1231	3	0
285	Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization - a Review. <i>Reviews in Cardiovascular Medicine</i> , 2019 , 20, 111-120	3.9	9
284	Alterations in Doppler-derived renal venous stasis index during recompensation of right heart failure and fluid overload in a patient with pulmonary hypertension. <i>Reviews in Cardiovascular Medicine</i> , 2019 , 20, 263-266	3.9	1
283	Heart-Kidney Cross-Talk 2019 , 664-670.e3		1
282	The CatLet score: a new coronary angiographic scoring tool accommodating the variable coronary anatomy for the first time. <i>Journal of Thoracic Disease</i> , 2019 , 11, 5199-5209	2.6	3
281	In-Hospital Mortality and Major Adverse Cardiovascular Events after Kidney Transplantation in the United States. <i>CardioRenal Medicine</i> , 2019 , 9, 51-60	2.8	15
280	Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson Disease. <i>Cardiology and Therapy</i> , 2019 , 8, 145-150	2.8	3
279	Rate of major adverse renal or cardiac events with iohexol compared to other low osmolar contrast media during interventional cardiovascular procedures. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, E90-E97	2.7	1
278	Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 90-99	4.3	49
277	Major Adverse Renal and Cardiac Events After Coronary Angiography and Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2018 , 105, 1724-1730	2.7	8
276	Efficacy of Subcutaneous Versus Intravenous Administration of Furosemide in Patients With Worsening Heart Failure: The Devil Is in the Details. <i>JACC: Heart Failure</i> , 2018 , 6, 266-267	7.9	4
275	The Role of Dendritic and Endothelial Cells in Cardiorenal Syndrome. <i>CardioRenal Medicine</i> , 2018 , 8, 92-104	10.8	12
274	Preeclampsia as a Form of Type 5 Cardiorenal Syndrome: An Underrecognized Entity in Women's Cardiovascular Health. <i>CardioRenal Medicine</i> , 2018 , 8, 160-172	2.8	12
273	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). <i>American Journal of Cardiology</i> , 2018 , 121, 940-948	3	13
272	Iso-osmolar contrast media and adverse renal and cardiac events after percutaneous cardiovascular intervention. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 331-341	2.1	6

271	Perioperative THR-184 and AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 670-679	12.7	20
270	Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials. <i>Kidney International Supplements</i> , 2018 , 8, 8-17	6.3	6
269	Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia. <i>Baylor University Medical Center Proceedings</i> , 2018 , 31, 180-184	0.6	6
268	Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy. <i>Postgraduate Medicine</i> , 2018 , 130, 299-307	3.7	13
267	Clinical Impact of Changes in Hemodynamic Indices of Contractile Function During Treatment of Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2018 , 24, 43-50	3.3	7
266	Detection of Atherosclerotic Cardiovascular Disease in Patients with Advanced Chronic Kidney Disease in the Cardiology and Nephrology Communities. <i>CardioRenal Medicine</i> , 2018 , 8, 285-295	2.8	4
265	FP071SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i72-i72	4.3	3
264	Semaglutide and GLP-1 analogues as weight-loss agents. <i>Lancet, The</i> , 2018 , 392, 615-616	4.0	5
263	Cardionephrology: Proposal for a Futuristic Educational Approach to a Contemporary Need. <i>CardioRenal Medicine</i> , 2018 , 8, 296-301	2.8	11
262	Identifying suspected familial chylomicronemia syndrome. <i>Baylor University Medical Center Proceedings</i> , 2018 , 31, 284-288	0.6	4
261	Frequency of atrial arrhythmias after atrial flutter ablation and the effect of presenting rhythm on the day of ablation. <i>Baylor University Medical Center Proceedings</i> , 2018 , 31, 280-283	0.6	2
260	Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen. <i>Reviews in Cardiovascular Medicine</i> , 2018 , 19, 13-19	3.9	5
259	Bioimpedance-Guided Hydration for the Prevention of Contrast-Induced Kidney Injury: The HYDRA Study. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2880-2889	15.1	30
258	The effect of major adverse renal cardiovascular event (MARCE) incidence, procedure volume, and unit cost on the hospital savings resulting from contrast media use in inpatient angioplasty. <i>Journal of Medical Economics</i> , 2018 , 21, 356-364	2.4	4
257	Prognostic value of urinary 11-dehydro-thromboxane B for mortality: A cohort study of stable coronary artery disease patients treated with aspirin. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 92, 653-658	2.7	2
256	Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure. <i>Nephron</i> , 2018 , 138, 173-175	3.3	6
255	Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults. <i>Critical Care Medicine</i> , 2018 , 46, 375-383	1.4	34
254	Resuscitation for the specialty of nephrology: is cardionephrology the answer?. <i>Kidney International</i> , 2018 , 93, 25-26	9.9	10

253	FP152EFFECT OF BARDOXOLONE METHYL TREATMENT ON URINARY ALBUMIN IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE - POST-HOC ANALYSIS FROM BEAM AND BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i27-i27	4.3	1
252	Analysis of electrocardiographic intervals before and after transcatheter aortic valve implantation to predict the need for permanent pacing. <i>Baylor University Medical Center Proceedings</i> , 2018 , 31, 407-413	9.6	2
251	FP804TWO-YEAR DURABILITY OF IMPROVEMENTS IN EGFR WITH BARDOXOLONE METHYL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: THE LARIAT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i634-i634	4.3	
250	Heart Failure in End-Stage Kidney Disease: Pathophysiology, Diagnosis, and Therapeutic Strategies. <i>Seminars in Nephrology</i> , 2018 , 38, 600-617	4.8	26
249	SP421SODIUM ZIRCONIUM CYCLOSILICATE FOR HYPERKALAEMIA IN PATIENTS WITH DIABETES MELLITUS: RETROSPECTIVE ANALYSIS OF A 12 MONTH OPEN LABEL, PHASE 3 STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i489-i490	4.3	3
248	Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure. <i>American Journal of Cardiology</i> , 2018 , 122, 683-688	3	9
247	Effects of sodium glucose co-transporter 2 inhibitors on the kidney. <i>Diabetes and Vascular Disease Research</i> , 2018 , 15, 375-386	3.3	24
246	Contemporary practice patterns related to the risk of acute kidney injury in the catheterization laboratory: Results from a survey of Society of Cardiovascular Angiography and Intervention (SCAI) cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 383-392	2.7	7
245	Urinary 11-Dehydro-Thromboxane B and Mortality in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2017 , 119, 972-977	3	13
244	Volume expansion and contrast-induced acute kidney injury. <i>Lancet, The</i> , 2017 , 389, 1277-1278	4.0	7
243	Renal Function and Scaled Troponin in Patients Presenting to the Emergency Department with Symptoms of Myocardial Infarction. <i>American Journal of Nephrology</i> , 2017 , 45, 304-309	4.6	6
242	The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome. <i>CardioRenal Medicine</i> , 2017 , 7, 104-117	2.8	32
241	Residual thromboxane activity and oxidative stress: influence on mortality in patients with stable coronary artery disease. <i>Coronary Artery Disease</i> , 2017 , 28, 287-293	1.4	6
240	Reply: Vitamin E May Protect Against Contrast-Induced Acute Kidney Injury. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1878-1879	15.1	
239	Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>Journal of the American Society of Hypertension</i> , 2017 , 11, 783-800		33
238	Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 844-858	7.4	37
237	Relation between proprotein convertase subtilisin/kexin type 9 and directly measured low-density lipoprotein cholesterol. <i>Baylor University Medical Center Proceedings</i> , 2017 , 30, 16-20	0.6	3
236	Urinary metabolites in patients undergoing coronary catheterization via the radial versus femoral artery approach. <i>Baylor University Medical Center Proceedings</i> , 2017 , 30, 404-409	0.6	1

235	Personalized treatment of heart failure with biomarker guidance using a novel disease severity score. <i>Baylor University Medical Center Proceedings</i> , 2017 , 30, 139-142	0.6	4
234	Interpretation of positive troponin results among patients with and without myocardial infarction. <i>Baylor University Medical Center Proceedings</i> , 2017 , 30, 11-15	0.6	0
233	Prevalence of Hyperuricemia in Patients With Acute Heart Failure With Either Reduced or Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2017 , 120, 1146-1150	3	30
232	Current Risk of Contrast-Induced Acute Kidney Injury After Coronary Angiography and Intervention: A Reappraisal of the Literature. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1225-1228	3.8	46
231	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. <i>Current Atherosclerosis Reports</i> , 2017 , 19, 62	6	31
230	Optimal cut points of plasma and urine neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury among critically ill adults: retrospective determination and clinical validation of a prospective multicentre study. <i>BMJ Open</i> , 2017 , 7, e016028	3	22
229	Plasma Volume and Renal Function Predict Six-Month Survival after Hospitalization for Acute Decompensated Heart Failure. <i>CardioRenal Medicine</i> , 2017 , 8, 61-70	2.8	6
228	Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia. <i>Reviews in Cardiovascular Medicine</i> , 2017 , 18, 21-28	3.9	4
227	Spontaneous Coronary Artery Dissection: A Review of Pathogenesis, Presentations, Treatment, and Outcomes. <i>Reviews in Cardiovascular Medicine</i> , 2017 , 18, 29-36	3.9	3
226	Hyperuricemia and Cardiovascular Disease. <i>Reviews in Cardiovascular Medicine</i> , 2017 , 18, 134-145	3.9	
225	A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. <i>Reviews in Cardiovascular Medicine</i> , 2017 , 18, 93-99	3.9	4
224	ABT-719 for the Prevention of Acute Kidney Injury in Patients Undergoing High-Risk Cardiac Surgery: A Randomized Phase 2b Clinical Trial. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	23
223	Contrast-Induced Acute Kidney Injury. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1465-1473	15.1	192
222	Comparative Efficacy of Transradial Versus Transfemoral Approach for Coronary Angiography and Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016 , 118, 482-8	3	10
221	Intensive Hemodialysis and Treatment Complications and Tolerability. <i>American Journal of Kidney Diseases</i> , 2016 , 68, S43-S50	7.4	44
220	Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. <i>American Journal of Kidney Diseases</i> , 2016 , 68, S5-S14	7.4	71
219	Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. <i>American Journal of Kidney Diseases</i> , 2016 , 68, S15-S23	7.4	27
218	Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 2079-2084	6.9	17

217	Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use. <i>American Journal of Kidney Diseases</i> , 2016 , 68, S24-S32	7.4	27
216	Arrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 721-34	6.9	42
215	Impact of Enhanced External Counterpulsation on Heart Failure Rehospitalization in Patients With Ischemic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2016 , 117, 901-5	3	3
214	Aging Male Spontaneously Hypertensive Rat as an Animal Model for the Evaluation of the Interplay between Contrast-Induced Acute Kidney Injury and Cardiorenal Syndrome in Humans. <i>CardioRenal Medicine</i> , 2016 , 7, 1-10	2.8	7
213	Frequency of fluid overload and usefulness of bioimpedance in patients requiring intensive care for sepsis syndromes. <i>Baylor University Medical Center Proceedings</i> , 2016 , 29, 12-5	0.6	7
212	Lipoic Acid in the Prevention of Acute Kidney Injury. <i>Nephron</i> , 2016 , 134, 133-140	3.3	25
211	Oxidative stress reflected by increased F-isoprostanes is associated with increasing urinary 11-dehydro thromboxane B levels in patients with coronary artery disease. <i>Thrombosis Research</i> , 2016 , 148, 85-88	8.2	8
210	Atrophy of the Heart After Insertion of a Left Ventricular Assist Device and Closure of the Aortic Valve. <i>American Journal of Cardiology</i> , 2016 , 117, 878-9	3	2
209	Chronic kidney disease from screening, detection, and awareness, to prevention. <i>The Lancet Global Health</i> , 2016 , 4, e288-9	13.6	11
208	Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. <i>American Journal of Medicine</i> , 2016 , 129, 858-65	2.4	27
207	Prognostic Significance of Hyperuricemia in Patients With Acute Heart Failure. <i>American Journal of Cardiology</i> , 2016 , 117, 1616-1621	3	32
206	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016 , 2, 200-5	6.4	21
205	Nutritional Deficiencies and Sarcopenia in Heart Failure: A Therapeutic Opportunity to Reduce Hospitalization and Death. <i>Reviews in Cardiovascular Medicine</i> , 2016 , 17 Suppl 1, S30-S39	3.9	4
204	Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 196-205	7.4	28
203	Loop diuretics in acute heart failure: beyond the decongestive relief for the kidney. <i>Critical Care</i> , 2015 , 19, 296	10.8	31
202	A Review of the Use of Iloprost, A Synthetic Prostacyclin, in the Prevention of Radiocontrast Nephropathy in Patients Undergoing Coronary Angiography and Intervention. <i>Clinical Cardiology</i> , 2015 , 38, 492-8	3.3	12
201	Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 1050-6	12.3	98
200	Cardiorenal Syndromes: Advances in Determining Diagnosis, Prognosis and Therapy. <i>Journal of Cardiovascular Diseases & Diagnosis</i> , 2015 , 03,	0	3

199	Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2433-48	15.1	117
198	Subclinical and clinical contrast-induced acute kidney injury: data from a novel blood marker for determining the risk of developing contrast-induced nephropathy (ENCINO), a prospective study. <i>Renal Failure</i> , 2015 , 37, 187-91	2.9	16
197	Novel markers and therapies for patients with acute heart failure and renal dysfunction. <i>American Journal of Medicine</i> , 2015 , 128, 312.e1-22	2.4	9
196	Understanding and Managing Atrial Fibrillation in Patients with Kidney Disease. <i>Journal of Atrial Fibrillation</i> , 2015 , 7, 1069	0.8	3
195	Pre-procedural bioimpedance vectorial analysis of fluid status and prediction of contrast-induced acute kidney injury. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1387-94	15.1	24
194	Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1246-1252	15.1	42
193	Peter Andrew McCullough, MD, MPH: an interview with the editor. <i>American Journal of Cardiology</i> , 2014 , 114, 1772-85	3	0
192	Reducing contrast-induced acute kidney injury using a regional multicenter quality improvement intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 693-700	5.8	44
191	The management of acute coronary syndromes in patients with chronic kidney disease. <i>Advances in Chronic Kidney Disease</i> , 2014 , 21, 472-9	4.7	7
190	Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. <i>Journal of Cardiac Failure</i> , 2014 , 20, 953-8	3.3	115
189	Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 2054-61	4.3	180
188	Contrast-Induced Nephropathy: Definitions, Epidemiology, and Implications. <i>Interventional Cardiology Clinics</i> , 2014 , 3, 357-362	1.4	6
187	Calling for targeted trials in cardiorenal syndromes. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 10-2	7.4	1
186	Endothelial cell autoantibodies in predicting declining renal function, end-stage renal disease, or death in adult type 2 diabetic nephropathy. <i>Frontiers in Endocrinology</i> , 2014 , 5, 128	5.7	6
185	Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. <i>Kidney International</i> , 2014 , 85, 686-92	9.9	51
184	Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. <i>American Journal of Nephrology</i> , 2014 , 39, 499-508	4.6	109
183	Continuous versus bolus intermittent loop diuretic infusion in acutely decompensated heart failure: a prospective randomized trial. <i>Critical Care</i> , 2014 , 18, R134	10.8	42
182	Practical experience using galectin-3 in heart failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014 , 52, 1425-31	5.9	21

181	Cardiac and renal fibrosis in chronic cardiorenal syndromes. <i>Nephron Clinical Practice</i> , 2014 , 127, 106-12		27
180	Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. <i>Cardiovascular Diagnosis and Therapy</i> , 2014 , 4, 224-31	2.6	8
179	Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. <i>Reviews in Cardiovascular Medicine</i> , 2014 , 15, 11-23	3.9	42
178	Utilization of galectin-3 in case management across the spectrum of heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2014 , 15, 197-207	3.9	
177	New vistas for the treatment of obesity: turning the tide against the leading cause of morbidity and cardiovascular mortality in the developed world. <i>Reviews in Cardiovascular Medicine</i> , 2014 , 15 Suppl 2, S1-19; quiz S20-1	3.9	1
176	Advanced lipid testing: when, why, and in whom?. <i>Reviews in Cardiovascular Medicine</i> , 2014 , 15, 310-7; quiz 318-9	3.9	2
175	The Current and Future Landscape of Urinary Thromboxane Testing to Evaluate Atherothrombotic Risk. <i>Reviews in Cardiovascular Medicine</i> , 2014 , 15, 119-130	3.9	4
174	Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013 , 182, 117-36	1.6	74
173	Cardiorenal syndrome type 5: clinical presentation, pathophysiology and management strategies from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013 , 182, 174-94	1.6	30
172	Cardiorenal syndrome type 3: pathophysiologic and epidemiologic considerations. <i>Contributions To Nephrology</i> , 2013 , 182, 137-57	1.6	52
171	Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. <i>American Journal of Nephrology</i> , 2013 , 37, 549-58	4.6	88
170	Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. <i>Critical Care</i> , 2013 , 17, R25	10.8	718
169	The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2013 , 61, S12-23	7.4	51
168	Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013 , 182, 5-12	1.6	77
167	Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. <i>Contributions To Nephrology</i> , 2013 , 182, 13-29	1.6	171
166	Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013 , 182, 82-98	1.6	101
165	Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013 , 182, 99-116	1.6	64
164	Cardiorenal syndrome type 4: insights on clinical presentation and pathophysiology from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2013 , 182, 158-73	1.6	42

163	Urine catalytic iron and neutrophil gelatinase-associated lipocalin as companion early markers of acute kidney injury after cardiac surgery: a prospective pilot study. <i>CardioRenal Medicine</i> , 2013 , 3, 7-16	2.8	17
162	Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function. <i>Clinical Cardiology</i> , 2013 , 36, 611-20	3.3	16
161	Prevention of contrast-induced AKI: a review of published trials and the design of the prevention of serious adverse events following angiography (PRESERVE) trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 1618-31	6.9	71
160	Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. <i>Archives of Internal Medicine</i> , 2012 , 172, 246-53		106
159	Chronic kidney disease as a risk factor for acute coronary syndromes in patients presenting to the emergency room with chest pain. <i>Translational Research</i> , 2012 , 159, 391-6	11	5
158	Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP). <i>BMC Nephrology</i> , 2012 , 13, 104	2.7	9
157	Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1031-42	15.1	268
156	Phidippides cardiomyopathy: a review and case illustration. <i>Clinical Cardiology</i> , 2012 , 35, 69-73	3.3	32
155	Neutrophil gelatinase-associated lipocalin: a novel marker of contrast nephropathy risk. <i>American Journal of Nephrology</i> , 2012 , 35, 509-14	4.6	29
154	Diagnosis of cardiovascular disease in patients with chronic kidney disease. <i>Blood Purification</i> , 2012 , 33, 112-8	3.1	6
153	Cardiovascular damage resulting from chronic excessive endurance exercise. <i>Missouri Medicine</i> , 2012 , 109, 312-21	0.8	31
152	B-Type Natriuretic Peptide: Beyond Diagnostic Applications 2012 , 67-77		5
151	Determinants of markedly increased B-type natriuretic peptide in patients with ST-segment elevation myocardial infarction. <i>American Journal of Emergency Medicine</i> , 2011 , 29, 141-7	2.9	4
150	Changes in renal markers and acute kidney injury after marathon running. <i>Nephrology</i> , 2011 , 16, 194-9	2.2	85
149	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011 , 57, S9-16	7.4	98
148	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: prevalence of and risk factors for diabetes mellitus in CKD in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011 , 57, S24-31	7.4	21
147	Sustainable community-based CKD screening methods employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011 , 57, S4-8	7.4	19
146	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2010: executive summary. <i>American Journal of Kidney Diseases</i> , 2011 , 57, S1-3	7.4	7

145	Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP). <i>Current Diabetes Reports</i> , 2011 , 11, 47-55	5.6	34
144	Patient discomfort associated with the use of intra-arterial iodinated contrast media: a meta-analysis of comparative randomized controlled trials. <i>BMC Medical Imaging</i> , 2011 , 11, 12	2.9	25
143	Micronutrients and cardiorenal disease: insights into novel assessments and treatment. <i>Blood Purification</i> , 2011 , 31, 177-85	3.1	5
142	Cardiorenal syndromes. <i>World Journal of Cardiology</i> , 2011 , 3, 1-9	2.1	21
141	Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. <i>CardioRenal Medicine</i> , 2011 , 1, 45-52	2.8	12
140	Effects of Intra-Arterial and Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of Contrast-Induced Acute Kidney Injury: A Meta-Analysis. <i>CardioRenal Medicine</i> , 2011 , 1, 220-234	2.8	47
139	Influence of myocardial ischemia on outcomes in patients with systolic versus non-systolic heart failure. <i>American Journal of Cardiovascular Disease</i> , 2011 , 1, 167-75	0.9	3
138	Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2011 , 12, 200-10	3.9	101
137	Audiocardiography in the cardiovascular evaluation of the morbidly obese. <i>Clinical Physiology and Functional Imaging</i> , 2010 , 30, 369-374	2.4	2
136	Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. <i>Internal Medicine Journal</i> , 2010 , 40, 833-41	1.6	5
135	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 1777-84	4.3	29
134	Impact of reduced kidney function on cardiopulmonary fitness in patients with systolic heart failure. <i>American Journal of Nephrology</i> , 2010 , 32, 226-33	4.6	16
133	Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2010 , 165, 54-67	1.6	85
132	Prevention of cardiorenal syndromes. <i>Contributions To Nephrology</i> , 2010 , 165, 101-111	1.6	6
131	Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. <i>Postgraduate Medicine</i> , 2010 , 122, 25-34	3.7	23
130	Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 425-38	2.5	23
129	Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. <i>European Heart Journal</i> , 2010 , 31, 703-11	9.5	581
128	Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease. <i>Seminars in Nephrology</i> , 2010 , 30, 66-73	4.8	33

127	Acute cardiac effects of marathon running. <i>Journal of Applied Physiology</i> , 2010 , 108, 1148-53	3.7	169
126	Myocardial ischemia in patients with diastolic dysfunction and heart failure. <i>Current Cardiology Reports</i> , 2010 , 12, 216-22	4.2	20
125	Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010 , 55, S23-33	7.4	194
124	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) annual data report 2009: executive summary. <i>American Journal of Kidney Diseases</i> , 2010 , 55, S1-3	7.4	146
123	Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 51-8	2.3	25
122	Integration of the clinical laboratory in cardiovascular medicine. <i>Reviews in Cardiovascular Medicine</i> , 2010 , 11 Suppl 2, S1-2	3.9	2
121	Differential diagnosis and overlap of acute chest discomfort and dyspnea in the emergency department. <i>Reviews in Cardiovascular Medicine</i> , 2010 , 11 Suppl 2, S13-23	3.9	3
120	Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers. <i>Reviews in Cardiovascular Medicine</i> , 2010 , 11 Suppl 2, S3-12	3.9	
119	An evidence-based algorithm for the use of B-type natriuretic testing in acute coronary syndromes. <i>Reviews in Cardiovascular Medicine</i> , 2010 , 11 Suppl 2, S51-65	3.9	3
118	Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. <i>Nature Reviews Cardiology</i> , 2009 , 6, 301-11	14.8	77
117	Peak oxygen consumption and heart rate recovery in patients with the obstructive sleep apnea syndrome. <i>Chest</i> , 2009 , 135, 584-585	5.3	
116	Annual progression of coronary calcification in trials of preventive therapies: a systematic review. <i>Archives of Internal Medicine</i> , 2009 , 169, 2064-70		54
115	Hazards of contrast-induced acute kidney injury in elderly women. <i>Women's Health</i> , 2009 , 5, 123-5	3	
114	Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 361-8	6.9	92
113	Serum cystatin C, renal filtration function, and left ventricular remodeling. <i>Circulation: Heart Failure</i> , 2009 , 2, 86-9	7.6	14
112	Serum cystatin C in the estimation of glomerular filtration on chronic angiotensin-converting enzyme inhibitor therapy: an illustrative case report. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 651-5	2.3	1
111	Executive summary: Kidney Early Evaluation Program (KEEP) 2008 annual data report. <i>American Journal of Kidney Diseases</i> , 2009 , 53, S1-2	7.4	8
110	Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?. <i>Current Atherosclerosis Reports</i> , 2009 , 11, 334-7	6	17

109	Etiology and pathophysiology of new-onset heart failure: evaluation by myocardial perfusion imaging. <i>Journal of Nuclear Cardiology</i> , 2009 , 16, 82-91	2.1	41
108	Questionnaire instrument to assess knowledge of chronic kidney disease clinical practice guidelines among internal medicine residents. <i>Journal of Evaluation in Clinical Practice</i> , 2009 , 15, 733-8	2.5	5
107	Review article: Risks of coronary artery calcification in chronic kidney disease: do the same rules apply?. <i>Nephrology</i> , 2009 , 14, 428-36	2.2	18
106	Impact of treating the metabolic syndrome on chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2009 , 5, 520-8	14.9	41
105	Comprehensive Review of the Relative Clinical Utility of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide Assays in Cardiovascular Disease 2009 , 2, 6-17		7
104	Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes. <i>EuroIntervention</i> , 2009 , 5, 336-42	3.1	30
103	Lipoproteins, inflammatory biomarkers, and cardiovascular imaging in the assessment of atherosclerotic disease activity. <i>Reviews in Cardiovascular Medicine</i> , 2009 , 10, 51-8	3.9	0
102	Multimodality prevention of contrast-induced acute kidney injury. <i>American Journal of Kidney Diseases</i> , 2008 , 51, 169-72	7.4	19
101	CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008 , 51, S38-45	7.4	107
100	Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008 , 51, S56-68	7.4	48
99	Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. <i>American Journal of Kidney Diseases</i> , 2008 , 51, S46-55	7.4	72
98	CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2008 , 52, 382-3	7.4	34
97	Awareness and knowledge of clinical practice guidelines for CKD among internal medicine residents: a national online survey. <i>American Journal of Kidney Diseases</i> , 2008 , 52, 1061-9	7.4	47
96	Impact of obesity on cardiovascular disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008 , 37, 663-84, ix	5.5	83
95	Contrast-induced acute kidney injury. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 1419-28	15.1	703
94	Obesity and age of first non-ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 979-85	15.1	110
93	Chronic kidney disease as a cardiovascular risk state and considerations for the use of statins. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 318-27	4.9	1
92	Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. <i>American Heart Journal</i> , 2008 , 156, 277-83	4.9	116

91	Amplification of atherosclerotic calcification and MückebergB sclerosis: a spectrum of the same disease process. <i>Advances in Chronic Kidney Disease</i> , 2008 , 15, 396-412	4.7	21
90	Cardiorespiratory fitness and obstructive sleep apnea syndrome in morbidly obese patients. <i>Chest</i> , 2008 , 134, 539-545	5.3	46
89	Radiocontrast-induced acute kidney injury. <i>Nephron Physiology</i> , 2008 , 109, p61-72		65
88	New therapeutic agents for diabetic kidney disease. <i>Therapy: Open Access in Clinical Medicine</i> , 2008 , 5, 553-575		4
87	Accelerated atherosclerotic calcification and MonckebergB sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 1585-98	6.9	119
86	Acute kidney injury with iodinated contrast. <i>Critical Care Medicine</i> , 2008 , 36, S204-11	1.4	59
85	Lipids, biomarkers, and noninvasive imaging of atherosclerotic disease activity in clinical trials. <i>Reviews in Cardiovascular Medicine</i> , 2008 , 9, 142-9	3.9	5
84	Statin therapy in renal disease: harmful or protective?. <i>Current Atherosclerosis Reports</i> , 2007 , 9, 18-24	6	9
83	Statin therapy in renal disease: harmful or protective?. <i>Current Diabetes Reports</i> , 2007 , 7, 467-73	5.6	2
82	Coronary artery disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007 , 2, 611-6	6.9	54
81	Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). <i>Archives of Internal Medicine</i> , 2007 , 167, 1122-9		144
80	Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure. <i>American Heart Journal</i> , 2007 , 153, 189-200	4.9	49
79	Residual high-grade angina after enhanced external counterpulsation therapy. <i>Cardiovascular Revascularization Medicine</i> , 2007 , 8, 161-5	1.6	1
78	Cardiorenal intersection: crossroads to the future. <i>Arquivos Brasileiros De Cardiologia</i> , 2007 , 88, 117-26	1.2	2
77	Estimated glomerular filtration rate: why is it important?. <i>Reviews in Cardiovascular Medicine</i> , 2007 , 8, 46-9	3.9	
76	The rosiglitazone meta-analysis. <i>Reviews in Cardiovascular Medicine</i> , 2007 , 8, 123-6	3.9	3
75	Overview of B-type natriuretic peptide as a blood test. Roundtable discussion. <i>Congestive Heart Failure</i> , 2006 , 12, 99-102		1
74	Epidemiology and prognostic implications of contrast-induced nephropathy. <i>American Journal of Cardiology</i> , 2006 , 98, 5K-13K	3	286

73	Risk prediction of contrast-induced nephropathy. <i>American Journal of Cardiology</i> , 2006 , 98, 27K-36K	3	280
72	Do implantable cardioverter-defibrillators improve survival in dialysis patients after cardiac arrest?. <i>Nature Clinical Practice Nephrology</i> , 2006 , 2, 70-1		1
71	Chronic kidney disease: tipping the scale to the benefit of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. <i>Circulation</i> , 2006 , 114, 6-7	16.7	13
70	Primer: practical approach to the selection of patients for and application of EECF. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006 , 3, 623-32		26
69	Renal safety of iodixanol. <i>Expert Review of Cardiovascular Therapy</i> , 2006 , 4, 655-61	2.5	9
68	Impact of body mass index on outcomes of enhanced external counterpulsation therapy. <i>American Heart Journal</i> , 2006 , 151, 139	4.9	11
67	Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. <i>American Heart Journal</i> , 2006 , 151, 1006-11	4.9	50
66	Cardiorespiratory fitness and short-term complications after bariatric surgery. <i>Chest</i> , 2006 , 130, 517-25	5.3	182
65	Ranolazine: focusing on angina pectoris. <i>Drugs of Today</i> , 2006 , 42, 177-83	2.5	2
64	Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. <i>Reviews in Cardiovascular Medicine</i> , 2006 , 7, 177-97	3.9	78
63	Contrast-induced nephropathy. <i>Critical Care Clinics</i> , 2005 , 21, 261-80	4.5	139
62	Changes in B-type natriuretic peptide levels in hemodialysis and the effect of depressed left ventricular function. <i>Advances in Chronic Kidney Disease</i> , 2005 , 12, 117-24	4.7	26
61	Substantial weight gain during adulthood: the road to bariatric surgery. <i>Preventive Cardiology</i> , 2005 , 8, 155-9		8
60	Bundle branch block patterns, age, renal dysfunction, and heart failure mortality. <i>International Journal of Cardiology</i> , 2005 , 102, 303-8	3.2	47
59	The relationship between B-type natriuretic peptide and health status in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2005 , 11, 414-21	3.3	45
58	Percutaneous coronary interventions in the high-risk renal patient: strategies for renal protection and vascular protection. <i>Cardiology Clinics</i> , 2005 , 23, 299-310	2.5	5
57	Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. <i>Kidney International</i> , 2005 , 67, 1483-8	9.9	116
56	Evaluation and treatment of coronary artery disease in patients with end-stage renal disease. <i>Kidney International</i> , 2005 , S51-8	9.9	14

55	Outcomes and prognostic factors of systolic as compared with diastolic heart failure in urban America. <i>Congestive Heart Failure</i> , 2005 , 11, 6-11		26
54	Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the Breathing Not Properly (BNP) Multinational Study. <i>American Journal of Hematology</i> , 2005 , 80, 174-80	7.1	45
53	Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2005 , 3, 743-59	2.5	8
52	Effect of lipid modification on progression of coronary calcification. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16 Suppl 2, S115-9	12.7	22
51	The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. <i>Reviews in Cardiovascular Medicine</i> , 2005 , 6, 1-10	3.9	15
50	Chronic angina: new medical options for treatment. <i>Reviews in Cardiovascular Medicine</i> , 2005 , 6, 152-61	3.9	4
49	Anemia: a modifiable risk factor for heart disease. Introduction. <i>Reviews in Cardiovascular Medicine</i> , 2005 , 6 Suppl 3, S1-3	3.9	3
48	Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. <i>Reviews in Cardiovascular Medicine</i> , 2005 , 6 Suppl 3, S4-12	3.9	13
47	B-type natriuretic peptide and its clinical implications in heart failure. <i>The American Heart Hospital Journal</i> , 2004 , 2, 26-33		6
46	Chronic kidney disease and sudden death: strategies for prevention. <i>Blood Purification</i> , 2004 , 22, 136-42	3.1	44
45	Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor?. <i>Kidney International</i> , 2004 , S18-24	9.9	21
44	Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. <i>Journal of Interventional Cardiology</i> , 2004 , 17, 81-6	1.8	22
43	BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. <i>Congestive Heart Failure</i> , 2004 , 10, 1-30		230
42	Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004 , 11, 199-204	2.4	89
41	Optimal dialysis for the end-stage renal disease patient with cardiovascular disease. <i>Advances in Chronic Kidney Disease</i> , 2004 , 11, 261-73	4.7	3
40	Cardiovascular risk reduction and preservation of renal function in the early nephropathy patient. <i>Advances in Chronic Kidney Disease</i> , 2004 , 11, 184-91	4.7	2
39	Opportunities for improvement in the cardiovascular care of patients with end-stage renal disease. <i>Advances in Chronic Kidney Disease</i> , 2004 , 11, 294-303	4.7	8
38	Slowing the progression of diabetic nephropathy and its cardiovascular consequences. <i>American Heart Journal</i> , 2004 , 148, 243-51	4.9	25

37	Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. <i>Current Opinion in Nephrology and Hypertension</i> , 2004 , 13, 591-600	3.5	44
36	Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2004 , 5, 16-25	3.9	22
35	Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation. <i>Reviews in Cardiovascular Medicine</i> , 2004 , 5, 99-103	3.9	3
34	Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. <i>Journal of Nephrology</i> , 2004 , 17, 205-15	4.8	96
33	Conventional risk factors and cardiac events--debunking an old myth about prevalence. <i>Reviews in Cardiovascular Medicine</i> , 2004 , 5, 185-6	3.9	
32	Preface. Ximelagatran and oral direct thrombin inhibition. <i>Reviews in Cardiovascular Medicine</i> , 2004 , 5 Suppl 5, S1	3.9	
31	Does quality of life evidence assist in the selection of patients for resynchronization therapy?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 71-6		4
30	B-type natriuretic peptide and renal disease. <i>Heart Failure Reviews</i> , 2003 , 8, 355-8	5	85
29	Opportunities for improvement in the diagnosis and treatment of heart failure. <i>Clinical Cardiology</i> , 2003 , 26, 231-7	3.3	10
28	Acute coronary syndromes in patients with renal failure. <i>Current Cardiology Reports</i> , 2003 , 5, 266-70	4.2	13
27	Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. <i>American Journal of Cardiology</i> , 2003 , 92, 509-14	3	135
26	Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. <i>American Journal of Cardiology</i> , 2003 , 92, 919-23	3	73
25	Uncovering Heart Failure in Patients with a History of Pulmonary Disease: Rationale for the Early Use of B-type Natriuretic Peptide in the Emergency Department. <i>Academic Emergency Medicine</i> , 2003 , 10, 198-204	3.4	56
24	Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. <i>Circulation</i> , 2003 , 108, 2154-69	16.7	2515
23	Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. <i>Academic Emergency Medicine</i> , 2003 , 10, 198-204	3.4	111
22	Beyond serum creatinine: defining the patient with renal insufficiency and why?. <i>Reviews in Cardiovascular Medicine</i> , 2003 , 4 Suppl 1, S2-6	3.9	9
21	B-type natriuretic peptides: a diagnostic breakthrough for clinicians. <i>Reviews in Cardiovascular Medicine</i> , 2003 , 4, 72-80	3.9	129
20	Angiotensin converting enzyme inhibitors and beta-blockers in African Americans with heart failure. <i>Ethnicity and Disease</i> , 2003 , 13, 331-6	1.8	1

19	Sorting out the evidence on natriuretic peptides. <i>Reviews in Cardiovascular Medicine</i> , 2003 , 4 Suppl 4, S13-9	3.9	15
18	Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. <i>Reviews in Cardiovascular Medicine</i> , 2003 , 4 Suppl 7, S3-S12	3.9	2
17	Epidemiology of contrast-induced nephropathy. <i>Reviews in Cardiovascular Medicine</i> , 2003 , 4 Suppl 5, S3-9	3.9	41
16	Determinants of serum creatinine trajectory in acute contrast nephropathy. <i>Journal of Interventional Cardiology</i> , 2002 , 15, 349-54	1.8	104
15	Application of a cardiac arrest score in patients with sudden death and ST segment elevation for triage to angiography and intervention. <i>Journal of Interventional Cardiology</i> , 2002 , 15, 257-61	1.8	26
14	Performance of Multiple Cardiac Biomarkers Measured in the Emergency Department in Patients with Chronic Kidney Disease and Chest Pain. <i>Academic Emergency Medicine</i> , 2002 , 9, 1389-1396	3.4	9
13	Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2002 , 3, 188-91	3	47
12	Emergency evaluation of chest pain in patients with advanced kidney disease. <i>Archives of Internal Medicine</i> , 2002 , 162, 2464-8		26
11	Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. <i>Journal of the American College of Cardiology</i> , 2002 , 39, 60-9	15.1	386
10	Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. <i>New England Journal of Medicine</i> , 2002 , 347, 161-7	59.2	2595
9	Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. <i>American Heart Journal</i> , 2002 , 144, 226-32	4.9	176
8	Performance of multiple cardiac biomarkers measured in the emergency department in patients with chronic kidney disease and chest pain. <i>Academic Emergency Medicine</i> , 2002 , 9, 1389-96	3.4	27
7	Cardiorenal risk: an important clinical intersection. <i>Reviews in Cardiovascular Medicine</i> , 2002 , 3, 71-6	3.9	65
6	Scope of cardiovascular complications in patients with kidney disease. <i>Ethnicity and Disease</i> , 2002 , 12, S3-44-8	1.8	3
5	Coronary calcification and cardiac events after percutaneous intervention in dialysis patients. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001 , 8, 133-7		11
4	Costs and outcomes of patients admitted with chest pain and essentially normal electrocardiograms. <i>Clinical Cardiology</i> , 1998 , 21, 22-6	3.3	25
3	Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. <i>American Journal of Medicine</i> , 1997 , 103, 368-75	2.4	1333
2	Rapid bedside coronary angiography with a portable fluoroscopic imaging system. <i>Catheterization and Cardiovascular Diagnosis</i> , 1997 , 41, 449-55		8

- 1 Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis